

Adherence to, knowledge and beliefs about drugs used to reduce phosphate absorption in dialysis patients

Submission date 10/04/2019	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 11/04/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 02/09/2020	Condition category Urological and Genital Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The majority of dialysis patients are using phosphate binders to prevent or reduce high phosphate blood levels. In this study we want to investigate adherence to, knowledge and beliefs about phosphate binder treatment in dialysis patients. We also want to investigate whether counselling about phosphate binder treatment changes these parameters and the phosphate blood levels.

Who can participate?

Dialysis patients aged 18 years or more, attending the Dialysis centre at Akershus universitetssykehus, can participate in the study.

What does the study involve?

All participants in the study will receive a one-to-one pharmacist-led education and counselling session. All participants will answer three questionnaires twice. These include questions about phosphate binders, adherence to phosphate binder treatment and beliefs about phosphate binder treatment.

What are the possible benefits and risks of participating?

The study is assumed to be of potential benefit for the participants by improving their knowledge about phosphate binders and their awareness of the importance of phosphate binder treatment.

There are no risks of participating in the study. Participation includes counselling by a pharmacist about phosphate binder treatment. Participants need to spend a bit of time answering questionnaires, during dialysis.

Where is the study run from?

The study is a cooperation between the Hospital pharmacy and the Dialysis centre at Akershus universitetssykehus.

When is the study starting and how long is it expected to run for?

The study started in May 2017 and the approximate duration of the trial was two months.

Who is funding the study?

The Hospital Pharmacies Enterprise, South Eastern Norway are paying the costs that the trial will incur.

Who is the main contact?

If you have any questions regarding the study, please contact Bodil Jahren Hjemas, bodil.jahren.hjemas@sykehusapotekene.no

Contact information

Type(s)

Public

Contact name

Mrs Bodil Jahren Hjemas

ORCID ID

<http://orcid.org/0000-0002-6956-2859>

Contact details

Sykehusapoteket Ahus

Postboks 35

Lørenskog

Norway

1478

+4767960302

bodil.jahren.hjemas@sykehusapotekene.no

Type(s)

Scientific

Contact name

Mrs Kathrin Bjerknes

Contact details

Sykehusapoteket Ahus

Postboks 35

Lørenskog

Norway

1478

+4740638644

Kathrin.Bjerknes@sykehusapotekene.no

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

2016/1996/REK sør-øst

Study information

Scientific Title

Interventional study to improve adherence to phosphate binder treatment in dialysis patients

Study objectives

A one-to-one pharmacist-led education and counselling can enhance adherence and lead to changes in serum phosphate in dialysis patients.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 20/12/2016, The Regional Committee for Medical and Health Research Ethics, REK sør-øst (Postboks 1130, Blindern, 0318 Oslo; +47 22 84 55 11; rek-sorost@medisin.uio.no), ref: 2016 /1996

Study design

A descriptive interventional single-centre single arm pre-post study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Other

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Kidney disease requiring dialysis

Interventions

Patients included in the study received a single half-hour one-to-one pharmacist-led education and personalized counselling session. A semi-structured counselling guide was used in the session. An educational leaflet based on this guide was offered to the included patients.

Intervention Type

Behavioural

Primary outcome measure

Change in the proportion of patients with serum phosphate below 1.80 mmol/L. Serum phosphate levels for five months prior to the intervention, and five months after were drawn from the medical records for included patients.

Secondary outcome measures

Change in the patient's knowledge, beliefs and adherence after the intervention measured by completion of questionnaires:

'Patient Knowledge'

'Medication Adherence Report Scale'

'Beliefs about Medicines Questionnaire'

The participants were asked to answer the questionnaires twice; at the time of inclusion and 3 - 4 weeks after the intervention.

Overall study start date

20/01/2016

Completion date

31/12/2017

Eligibility

Key inclusion criteria

1. Age > 18 years
2. Receiving chronic dialysis two to four times a week for at least five months
3. Using at least one self-administered phosphate binder
4. Able to speak, read and write Norwegian
5. Able to give informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

At study start 122 patients attended the hospital dialysis centre.

Total final enrolment

69

Key exclusion criteria

1. Life expectancy < 5 months

Date of first enrolment

22/05/2017

Date of final enrolment

27/06/2017

Locations

Countries of recruitment

Norway

Study participating centre

Akershus universitetssykehus HF Akershus University Hospital

Postboks 1000

Lørenskog

Norway

1478

Sponsor information

Organisation

The Hospital Pharmacies Enterprise, Sout Eastern Norway

Sponsor details

Stenersgate 1

PB. 79

Oslo

Norway

0050

+4723135200

post@sykehusapotekene.no

Sponsor type

Other

Website

<https://sykehusapotekene.no/>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

The Hospital Pharmacies Enterprise

Results and Publications

Publication and dissemination plan

We wish to submit a manuscript for publication in BMC Nephrology in spring 2019, including the main results from the study.

Intention to publish date

15/04/2019

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/05/2019	02/09/2020	Yes	No